integra lifesciences holdings corp. - IART
IART
Close Chg Chg %
12.21 -0.47 -3.85%
Pre-Market
11.74
-0.47 (3.85%)
Volume: 953.92K
Last Updated:
Jul 15, 2025, 4:00 PM EDT
Company Overview: integra lifesciences holdings corp. - IART
IART Key Data
| Open $12.37 | Day Range 11.68 - 12.45 |
| 52 Week Range 11.06 - 32.66 | Market Cap $978.40M |
| Shares Outstanding 77.71M | Public Float 65.64M |
| Beta 1.15 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.38 |
| Yield 0.00% | Dividend $6.37 |
| EX-DIVIDEND DATE Jul 2, 2015 | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.22M |
IART Performance
| 1 Week | -6.75% | ||
| 1 Month | 1.21% | ||
| 3 Months | -25.84% | ||
| 1 Year | -62.54% | ||
| 5 Years | -76.43% |
IART Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
13
Full Ratings ➔
About integra lifesciences holdings corp. - IART
Integra LifeSciences Holdings Corp. engages in the provision of regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians. It operates under the Codman Specialty Surgical (CSS) and Tissue Technologies (TT) segments. The CSS segment includes technologies and instrumentation used for neurosurgery, neurocritical care, and otolaryngology. The TT segment focuses on complex wound surgery, surgical reconstruction, and peripheral nerve repair. The company was founded by Richard E. Caruso in 1989 and is headquartered in Princeton, NJ.
IART At a Glance
Integra LifeSciences Holdings Corp.
1100 Campus Road
Princeton, New Jersey 08540
| Phone | 1-609-275-0500 | Revenue | 1.61B | |
| Industry | Medical Specialties | Net Income | -6,944,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 4.473% | |
| Fiscal Year-end | 12 / 2025 | Employees | 4,396 | |
| View SEC Filings |
IART Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.084 |
| Price to Book Ratio | 1.133 |
| Price to Cash Flow Ratio | 13.50 |
| Enterprise Value to EBITDA | 10.696 |
| Enterprise Value to Sales | 2.147 |
| Total Debt to Enterprise Value | 0.574 |
IART Efficiency
| Revenue/Employee | 366,361.92 |
| Income Per Employee | -1,579.618 |
| Receivables Turnover | 5.913 |
| Total Asset Turnover | 0.412 |
IART Liquidity
| Current Ratio | 1.173 |
| Quick Ratio | 0.708 |
| Cash Ratio | 0.297 |
IART Profitability
| Gross Margin | 55.805 |
| Operating Margin | 11.348 |
| Pretax Margin | -1.132 |
| Net Margin | -0.431 |
| Return on Assets | -0.178 |
| Return on Equity | -0.443 |
| Return on Total Capital | -0.197 |
| Return on Invested Capital | -0.226 |
IART Capital Structure
| Total Debt to Total Equity | 128.427 |
| Total Debt to Total Capital | 56.222 |
| Total Debt to Total Assets | 49.154 |
| Long-Term Debt to Equity | 88.201 |
| Long-Term Debt to Total Capital | 38.612 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Integra Lifesciences Holdings Corp. - IART
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 1.54B | 1.56B | 1.54B | 1.61B | |
Sales Growth
| +12.43% | +0.99% | -1.03% | +4.47% | |
Cost of Goods Sold (COGS) incl D&A
| 655.84M | 629.61M | 647.37M | 711.77M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 123.67M | 118.30M | 123.51M | 140.50M | |
Depreciation
| 43.23M | 40.10M | 40.90M | 42.40M | |
Amortization of Intangibles
| 80.44M | 78.20M | 82.61M | 98.10M | |
COGS Growth
| +16.60% | -4.00% | +2.82% | +9.95% | |
Gross Income
| 886.60M | 928.05M | 894.21M | 898.75M | |
Gross Income Growth
| +9.54% | +4.67% | -3.65% | +0.51% | |
Gross Profit Margin
| +57.48% | +59.58% | +58.01% | +55.80% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 611.08M | 655.25M | 633.54M | 715.99M | |
Research & Development
| 36.23M | 41.42M | 41.94M | 54.43M | |
Other SG&A
| 574.85M | 613.83M | 591.59M | 661.56M | |
SGA Growth
| +2.54% | +7.23% | -3.31% | +13.01% | |
Other Operating Expense
| - | - | - | 40.03M | - |
Unusual Expense
| (2.01M) | 9.57M | 108.68M | 153.56M | |
EBIT after Unusual Expense
| 277.54M | 263.24M | 111.95M | 29.20M | |
Non Operating Income/Expense
| (34.88M) | (7.11M) | 38.55M | 40.65M | |
Non-Operating Interest Income
| 192.00K | 5.13M | 9.36M | 9.92M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 27.98M | 42.23M | 69.43M | 88.09M | |
Interest Expense Growth
| -49.51% | +50.92% | +64.40% | +26.87% | |
Gross Interest Expense
| 29.18M | 43.63M | 71.83M | 92.59M | |
Interest Capitalized
| 1.20M | 1.40M | 2.40M | 4.50M | |
Pretax Income
| 214.68M | 213.89M | 81.07M | (18.24M) | |
Pretax Income Growth
| +129.55% | -0.36% | -62.10% | -122.50% | |
Pretax Margin
| +13.92% | +13.73% | +5.26% | -1.13% | |
Income Tax
| 45.60M | 33.34M | 13.33M | (11.29M) | |
Income Tax - Current - Domestic
| 43.31M | 28.04M | 13.82M | 1.07M | |
Income Tax - Current - Foreign
| 5.04M | 9.89M | 11.39M | 8.37M | |
Income Tax - Deferred - Domestic
| (16.52M) | (13.91M) | (18.97M) | (31.24M) | |
Income Tax - Deferred - Foreign
| 13.76M | 9.32M | 7.08M | 10.51M | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 169.07M | 180.55M | 67.74M | (6.94M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| 169.07M | 180.55M | 67.74M | (6.94M) | |
Net Income Growth
| +26.28% | +6.79% | -62.48% | -110.25% | |
Net Margin Growth
| +10.96% | +11.59% | +4.39% | -0.43% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 169.07M | 180.55M | 67.74M | (6.94M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 169.07M | 180.55M | 67.74M | (6.94M) | |
EPS (Basic)
| 1.9962 | 2.1754 | 0.8458 | -0.0902 | |
EPS (Basic) Growth
| +26.21% | +8.98% | -61.12% | -110.66% | |
Basic Shares Outstanding
| 84.70M | 83.00M | 80.09M | 77.01M | |
EPS (Diluted)
| 1.9778 | 2.1619 | 0.8432 | -0.0902 | |
EPS (Diluted) Growth
| +25.89% | +9.31% | -61.00% | -110.70% | |
Diluted Shares Outstanding
| 85.48M | 83.52M | 80.34M | 77.01M | |
EBITDA
| 399.19M | 391.10M | 344.15M | 323.26M | |
EBITDA Growth
| +20.08% | -2.03% | -12.01% | -6.07% | |
EBITDA Margin
| +25.88% | +25.11% | +22.32% | +20.07% |
Snapshot
| Average Recommendation | HOLD | Average Target Price | 17.375 | |
| Number of Ratings | 13 | Current Quarters Estimate | 0.577 | |
| FY Report Date | 09 / 2025 | Current Year's Estimate | 2.24 | |
| Last Quarter’s Earnings | 0.43 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 2.56 | Next Fiscal Year Estimate | 2.457 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 10 | 10 | 12 | 12 |
| Mean Estimate | 0.58 | 0.82 | 2.24 | 2.46 |
| High Estimates | 0.67 | 0.87 | 2.27 | 2.71 |
| Low Estimate | 0.53 | 0.73 | 2.22 | 2.33 |
| Coefficient of Variance | 6.69 | 5.01 | 0.65 | 4.25 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 3 | 3 | 3 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 6 | 6 | 6 |
| UNDERWEIGHT | 1 | 1 | 1 |
| SELL | 3 | 3 | 3 |
| MEAN | Hold | Hold | Hold |
SEC Filings for Integra Lifesciences Holdings Corp. - IART
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Integra Lifesciences Holdings Corp. - IART
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 14, 2025 | Berteloot Chantal Veillon EVP & CHRO | 15,549 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 14, 2025 | Jeffrey Alan Mosebrook SVP, Fin & Princ Acct Officer | 40,882 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 14, 2025 | Jeffrey Alan Mosebrook SVP, Fin & Princ Acct Officer | 35,368 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $23.95 per share | 847,063.60 |
| Mar 14, 2025 | Jeffrey Alan Mosebrook SVP, Fin & Princ Acct Officer | 35,677 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $23.95 per share | 854,464.15 |
| Mar 14, 2025 | Harvinder Singh EVP & PRESIDENT, INTERNATIONAL | 20,133 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 14, 2025 | Harvinder Singh EVP & PRESIDENT, INTERNATIONAL | 34,531 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 14, 2025 | Harvinder Singh EVP & PRESIDENT, INTERNATIONAL | 13,252 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 14, 2025 | Harvinder Singh EVP & PRESIDENT, INTERNATIONAL | 3,744 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $23.95 per share | 89,668.80 |
| Mar 14, 2025 | Harvinder Singh EVP & PRESIDENT, INTERNATIONAL | 4,391 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 14, 2025 | Michael McBreen EVP & President, CSS | 53,451 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $23.95 per share | 1,280,151.45 |
| Mar 14, 2025 | Lea Daniels Knight EVP & CHIEF FINANCIAL OFFICER | 61,139 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 14, 2025 | Robert T. Davis EVP & President, TT | 64,043 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $23.95 per share | 1,533,829.85 |
| Mar 14, 2025 | Michael McBreen EVP & President, CSS | 51,864 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $23.95 per share | 1,242,142.80 |
| Mar 14, 2025 | Michael McBreen EVP & President, CSS | 39,132 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 14, 2025 | Lea Daniels Knight EVP & CHIEF FINANCIAL OFFICER | 40,280 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $23.95 per share | 964,706.00 |
| Mar 14, 2025 | Michael McBreen EVP & President, CSS | 70,344 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 14, 2025 | Eric Ian Schwartz EVP, Chief Legal Officer & Sec | 56,020 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $23.95 per share | 1,341,679.00 |
| Mar 14, 2025 | Eric Ian Schwartz EVP, Chief Legal Officer & Sec | 57,200 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $23.95 per share | 1,369,940.00 |
| Mar 14, 2025 | Robert T. Davis EVP & President, TT | 26,310 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 14, 2025 | Robert T. Davis EVP & President, TT | 75,561 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |